Supplementary material for 'Sonelokimab, a novel IL-17A- and IL-17F-inhibiting nanobody for the treatment of moderate-to-severe hidradenitis suppurativa: a global, randomized, double-blind, placebo-controlled phase 2 clinical trial (MIRA)'

Name: Supplementary material for 'Sonelokimab, a novel IL-17A- and IL-17F-inhibiting nanobody for the treatment of moderate-to-severe hidradenitis suppurativa: a global, randomized, double-blind, placebo-controlled phase 2 clinical trial (MIRA)'
Creator: Alexa B. Kimball
Published: 2026-09-22T16:46:31.003Z
Keywords: Dermatology, Hidradenitis Suppurativa

Kimball, Alexa B.; Bechara, Falk G.; Porter, Martina; Prens, Errol; Jemec, Gregor B.E.; Krueger, James G.; Szepietowski, Jacek C.; Gooderham, Melinda; Pinter, Andreas; Gordon, Kenneth B.; Brennan, Nuala; Godwood, Alex; Cullen, Eva; Reich, Kristian; Kirby, Brian

doi:10.17632/wg2nnntgzx.1

Supplementary material for 'Sonelokimab, a novel IL-17A- and IL-17F-inhibiting nanobody for the treatment of moderate-to-severe hidradenitis suppurativa: a global, randomized, double-blind, placebo-controlled phase 2 clinical trial (MIRA)'

Published: 22 September 2026| Version 1 | DOI: 10.17632/wg2nnntgzx.1

Contributors:

Alexa B. Kimball, Falk G. Bechara, Martina Porter, Errol Prens, Gregor B.E. Jemec, James G. Krueger, Jacek C. Szepietowski, Melinda Gooderham, Andreas Pinter, Kenneth B. Gordon, Nuala Brennan, Alex Godwood, Eva Cullen, Kristian Reich, Brian Kirby

Description

Supplementary material for 'Sonelokimab, a novel IL-17A- and IL-17F-inhibiting nanobody for the treatment of moderate-to-severe hidradenitis suppurativa: a global, randomized, double-blind, placebo-controlled phase 2 clinical trial (MIRA)'

Supplementary material for 'Sonelokimab, a novel IL-17A- and IL-17F-inhibiting nanobody for the treatment of moderate-to-severe hidradenitis suppurativa: a global, randomized, double-blind, placebo-controlled phase 2 clinical trial (MIRA)'

Description

Files

Categories

Licence